23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › VANDA PHARMACEUTICALS INC. › 2023-2024

VANDA PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and VANDA PHARMACEUTICALS INC.’s Form 8-K, filed May 20, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 172Asset managers, any item
  • 1,088Fund votes
  • May 17, 2024Meeting date

Results at a glance

Meeting of May 17, 2024: 5 items on VANDA PHARMACEUTICALS INC.’s Form 8-K, filed May 20, 2024: 1 elected · 3 approved · 1 failed (calculated).

Dissent

Significant dissent: 2 directors (53.2%, 20.8% against).

Notable dissent: 1 say-on-pay vote (78.7% support); 1 other board item (19.9% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore VANDA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by VANDA PHARMACEUTICALS INC.

These tallies are VANDA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VANDA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 17, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Mihael H. Polymeropoulos, M.D. 33,976,2398,943,623133,346 --4,923,082 79%Elected—
Elect Director: Phaedra S. Chrousos 20,071,82822,780,322201,058 --4,923,082 46.8%Failed (calculated)—
2. Ratification of Selection of PricewaterhouseCoopers LLP 44,750,5881,739,2951,486,407 ---- 96%Approved—
3. Advisory Vote on Named Executive Officer Compensation 33,515,1199,093,168444,921 --4,923,082 79%Approved—
4. Amendment to the 2016 Plan 34,411,0328,565,70576,471 --4,923,082 80%Approved—

Source: VANDA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 20, 2024 — read the filing on EDGAR.

How asset managers voted at the VANDA PHARMACEUTICALS INC. 2023-2024 meeting

172 asset managers disclosed a vote on at least one VANDA PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Mihael H. Polymeropoulos, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST
FOR: 33,976,239AGAINST: 8,943,623
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To elect two Class III Directors: Mihael H. Polymeropoulos, M.D.

VANDA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mihael H. Polymeropoulos, M.D.”): 33,976,239 for, 8,943,623 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class III directors until the Company's 2027 annual meeting of stockholders.”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 13,272,533 for, 1,588,593 against.

FOR
FOR: 13,272,533AGAINST: 1,588,593
Largest asset managers voting on “To elect two Class III Directors: Mihael H. Polymeropoulos, M.D.” at VANDA PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,349,0280 00For
Vanguard3,328,6130 00For
Fidelity1,299,299114,584 00Mixed
Dimensional01,264,595 00Against
Federated Hermes675,5170 00For
Charles Schwab668,8610 00For
SEI514,2820 00For
BRIDGEWAY FUNDS INC355,1000 00For
Invesco312,5390 00For
Nationwide258,4490 00For
American Century252,3880 00For
Columbia Threadneedle243,9860 00For
Victory Capital216,7170 00For
EA Series Trust204,9810 00For
Equitable190,5620 00For
Prudential/PGIM177,0770 00For
Goldman Sachs155,9230 00For
TIAA0153,314 00Against
MFS141,0530 00For
QUANTITATIVE MASTER SERIES LLC104,6320 00For
MASTER INVESTMENT PORTFOLIO79,9300 00For
GuideStone72,0610 00For
TARGET PORTFOLIO TRUST62,0000 00For
Lincoln Financial47,1818,874 00Mixed
ALPS ETF Trust40,2690 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Elect Director: Phaedra S. Chrousos

Calculated outcomeDIRECTOR ELECTIONSFailed (calculated)

Combines 4 wordings of this item as funds reported it.

46.8% Majority: no · of votes cast

FOR 46.8%AGAINST
FOR: 20,071,828AGAINST: 22,780,322
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To elect two Class III Directors: Phaedra S. Chrousos

VANDA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Phaedra S. Chrousos”): 20,071,828 for, 22,780,322 against, per its Form 8-K filed May 20, 2024 (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Failed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for did not exceed votes against.
Support: 46.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 10,547,952 for, 4,313,174 against.

FORAGAINST
FOR: 10,547,952AGAINST: 4,313,174
Largest asset managers voting on “To elect two Class III Directors: Phaedra S. Chrousos” at VANDA PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,349,0280 00For
Vanguard3,315,61313,000 00For
Fidelity1,292,599121,284 00Mixed
Dimensional01,264,595 00Against
Federated Hermes675,5170 00For
Charles Schwab668,8610 00For
SEI514,2820 00For
BRIDGEWAY FUNDS INC0355,100 00Against
Invesco0312,539 00Against
Nationwide0258,449 00Against
American Century0252,388 00Against
Columbia Threadneedle0243,986 00Against
Victory Capital0216,717 00Against
EA Series Trust0204,981 00Against
Equitable97,88992,673 00Mixed
Prudential/PGIM177,0770 00For
Goldman Sachs0155,923 00Against
TIAA0153,314 00Against
MFS0141,053 00Against
QUANTITATIVE MASTER SERIES LLC104,6320 00For
MASTER INVESTMENT PORTFOLIO79,9300 00For
GuideStone072,061 00Against
TARGET PORTFOLIO TRUST62,0000 00For
Lincoln Financial056,055 00Against
ALPS ETF Trust040,269 00Against

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Amendment to the 2016 Plan

Official resultSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

80% Approved · of votes cast

FOR 80%AGAINST
FOR: 34,411,032AGAINST: 8,565,705
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: To approve an amendment to the Company's amended and restated 2016 Equity Incentive Plan, as amended (the "2016 Plan"), to increase the aggregate number of shares authorized for issuance under the 2016 Plan.

VANDA PHARMACEUTICALS INC.’s own tally for this item (“4. Amendment to the 2016 Plan”): 34,411,032 for, 8,565,705 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the 2016 Plan to increase the aggregate number of shares authorized for issuance under the 2016 Plan.”
Support: 80% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 13,504,770 for, 1,356,356 against.

FOR
FOR: 13,504,770AGAINST: 1,356,356
Largest asset managers voting on “To approve an amendment to the Company's amended and restated 2016 Equity Incentive Plan, as amended (the "201” at VANDA PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,349,0280 00For
Vanguard3,328,6130 00For
Fidelity1,413,8830 00For
Dimensional1,264,5950 00For
Federated Hermes0675,517 00Against
Charles Schwab668,8610 00For
SEI514,2820 00For
BRIDGEWAY FUNDS INC355,1000 00For
Invesco312,5390 00For
Nationwide258,4490 00For
American Century0252,388 00Against
Columbia Threadneedle0243,986 00Against
Victory Capital216,7170 00For
EA Series Trust204,9810 00For
Equitable190,5620 00For
Prudential/PGIM177,0770 00For
Goldman Sachs155,9230 00For
TIAA153,3140 00For
MFS0141,053 00Against
QUANTITATIVE MASTER SERIES LLC104,6320 00For
MASTER INVESTMENT PORTFOLIO79,9300 00For
GuideStone72,0610 00For
TARGET PORTFOLIO TRUST62,0000 00For
Lincoln Financial56,0550 00For
ALPS ETF Trust40,2690 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Advisory Vote on Named Executive Officer Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

79% Approved · of votes cast

FOR 79%AGAINST
FOR: 33,515,119AGAINST: 9,093,168

Prior year: 96.8% for (June 8, 2023 meeting) ▼ 18.2 pts

Details: description as filed, official tally, votes by 172 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPANY'S NAMED EXECUTIVE OFFICER COMPENSATION.

VANDA PHARMACEUTICALS INC.’s own tally for this item (“3. Advisory Vote on Named Executive Officer Compensation”): 33,515,119 for, 9,093,168 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved on an advisory, non-binding basis the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 64 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPANY'S NAMED EXECUTIVE OFFICER COMPENSATION.” at VANDA PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,349,0280 00For
Vanguard3,328,6130 00For
Fidelity1,413,8830 00For
Dimensional1,264,5950 00For
Federated Hermes675,5170 00For
Charles Schwab668,8610 00For
SEI514,2820 00For
BRIDGEWAY FUNDS INC0355,100 00Against
Invesco0312,539 00Against
Nationwide258,4490 00For
American Century0252,388 00Against
Columbia Threadneedle243,9860 00For
Victory Capital216,7170 00For
EA Series Trust204,9810 00For
Equitable190,5620 00For
Prudential/PGIM177,0770 00For
Goldman Sachs155,9230 00For
TIAA153,3140 00For
MFS141,0530 00For
QUANTITATIVE MASTER SERIES LLC104,6320 00For
MASTER INVESTMENT PORTFOLIO79,9300 00For
GuideStone72,0610 00For
TARGET PORTFOLIO TRUST62,0000 00For
Lincoln Financial56,0550 00For
ALPS ETF Trust40,2690 00For

Fund voting reports, all 64 managers: 13,928,619 for, 932,507 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 129 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPANY'S NAMED EXECUTIVE OFFICER COMPENSATION.” at VANDA PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,302,050170 00For
Renaissance3,005,4770 00For
DE Shaw1,362,8460 00For
TANG CAPITAL MANAGEMENT LLC01,282,341 00Against
GEODE CAPITAL MANAGEMENT, LLC1,272,8230 00For
ACADIAN ASSET MANAGEMENT LLC1,254,7780 00For
State Street1,131,3234,744 00For
Prudential/PGIM930,93012,400 00For
JACOBS LEVY EQUITY MANAGEMENT, INC899,1840 00For
Nantahala Capital Management, LLC808,3980 00For
Federated Hermes687,0263,290 00For
Charles Schwab668,8610 00For
Ensign Peak Advisors, Inc602,7880 00For
SEI516,6870 00For
Northern Trust439,9192,847 00For
Connor, Clark & Lunn Investment Management Ltd.441,1520 00For
Wellington390,7370 00For
BRIDGEWAY CAPITAL MANAGEMENT, LLC0355,100 00Against
APG Asset Management US Inc.00 354,5000Abstain
Invesco0327,372 00Against
Allianz0322,386 00Against
Two Sigma298,3970 00For
Dimensional298,3720 00For
MELLON INVESTMENTS Corp270,4310 00For
American Century0252,388 00Against

Institutional-manager reports, all 129 managers: 20,907,994 for, 2,877,525 against, 354,500 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Selection of PricewaterhouseCoopers LLP

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 44,750,588AGAINST: 1,739,295
Details: description as filed, official tally, votes by 64 asset managers

Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2024.

VANDA PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Selection of PricewaterhouseCoopers LLP”): 44,750,588 for, 1,739,295 against — passed, per its Form 8-K filed May 20, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection, by the Audit Committee of the Board, of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 64 asset managers below reported 14,655,976 for, 205,150 against.

FOR
FOR: 14,655,976AGAINST: 205,150
Largest asset managers voting on “To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers” at VANDA PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
BlackRock3,349,0280 00For
Vanguard3,328,6130 00For
Fidelity1,413,8830 00For
Dimensional1,264,5950 00For
Federated Hermes675,5170 00For
Charles Schwab668,8610 00For
SEI514,2820 00For
BRIDGEWAY FUNDS INC355,1000 00For
Invesco312,5390 00For
Nationwide258,4490 00For
American Century252,3880 00For
Columbia Threadneedle243,9860 00For
Victory Capital216,7170 00For
EA Series Trust0204,981 00Against
Equitable190,5620 00For
Prudential/PGIM177,0770 00For
Goldman Sachs155,9230 00For
TIAA153,3140 00For
MFS141,0530 00For
QUANTITATIVE MASTER SERIES LLC104,6320 00For
MASTER INVESTMENT PORTFOLIO79,9300 00For
GuideStone72,0610 00For
TARGET PORTFOLIO TRUST62,0000 00For
Lincoln Financial56,0550 00For
ALPS ETF Trust40,2690 00For

Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).

Largest VANDA PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 58,196,523 shares outstanding at the time of that meeting.

Fund voting reports: top VANDA PHARMACEUTICALS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPANY'S NAMED EXECUTIVE OFFICER COMPENSATION.”, 2023-2024
#Asset manager % of shares outstanding
1BlackRock 5.75%
2Vanguard 5.72%
3Fidelity 2.43%
4Dimensional 2.17%
5Federated Hermes 1.16%
6Charles Schwab 1.15%
7SEI 0.88%
8BRIDGEWAY FUNDS INC 0.61%
9Invesco 0.54%
10Nationwide 0.44%
Institutional-manager reports: top VANDA PHARMACEUTICALS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPANY'S NAMED EXECUTIVE OFFICER COMPENSATION.”, 2023-2024
#Asset manager % of shares outstanding
1BlackRock 5.67%
2Renaissance 5.16%
3DE Shaw 2.34%
4TANG CAPITAL MANAGEMENT LLC 2.20%
5GEODE CAPITAL MANAGEMENT, LLC 2.19%
6ACADIAN ASSET MANAGEMENT LLC 2.16%
7State Street 1.95%
8Prudential/PGIM 1.62%
9JACOBS LEVY EQUITY MANAGEMENT, INC 1.55%
10Nantahala Capital Management, LLC 1.39%

Reported VANDA PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

VANDA PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock, Inc.8,346,367 14.34%Proxy statement (DEF 14A), proxy filed April 29, 2024
Renaissance Technologies LLC3,681,125 6.33%Proxy statement (DEF 14A), proxy filed April 29, 2024
Vanguard Group3,587,139 6.16%Form 13F, quarter ended March 31, 2024
Mihael H. Polymeropoulos, M.D.2,739,017 4.71%Proxy statement (DEF 14A), proxy filed April 29, 2024
D.E. Shaw1,802,842 3.10%Form 13F, quarter ended March 31, 2024
Dimensional Fund Advisors1,721,635 2.96%Form 13F, quarter ended March 31, 2024
Geode Capital1,245,382 2.14%Form 13F, quarter ended March 31, 2024
State Street1,203,295 2.07%Form 13F, quarter ended March 31, 2024
Citadel Advisors800,539 1.38%Form 13F, quarter ended March 31, 2024
Charles Schwab668,180 1.15%Form 13F, quarter ended March 31, 2024

Percentages above are of 58,196,523 shares outstanding, as reported by VANDA PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At VANDA PHARMACEUTICALS INC.'s shareholder meeting held May 17, 2024, in the 2023-2024 proxy season, 172 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,088 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPANY'S NAMED EXECUTIVE OFFICER COMPENSATION. — VANDA PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 79% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: VANDA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 20, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VANDA PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

VANDA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “VANDA PHARMACEUTICALS (VNDA) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/vanda-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.